C difficile risk
Oral Bioavailability


PO: 10mg/kg/DAY given as a single dailyt dose on day 1 (max: 500mg/dose), then 5mg/kg/DAY given as a single daily dose on days 2-5 (max: 250mg/dose)Pharyngitis: 12 mg/kg/dose (max: 500mg/dose) once daily x 5 days

10mg/kg/DAY given as a single daily dose, Max: 500mg/DAY. Administer IV for at least 2 days then switch to oral.

IV: 10mg/kg.DAY given as a single daily doseOral: 10-20mg/kg/DAY given as a single daily dose.

Use with caution in hepatic impairment.

Dose adjustment not necessary. Use with caution if CrCl<10mL/minute.

General Information

Community acquired pneumonia, Pertussis, upper respiratory tract infections, Chlamidial infections, mycobacterial infections, Mycobacterium avium complex (MAC) prophylaxis in HIV patients

Monitor QTc in patients with increased risk.

Prolongation of QTc interval.

While less risk of interaction compared to other macrolides, several potential CYP450 interactions may occur; consult a pharmacist for for more details.

Avoid concurrent use with other drugs that prolong QTc

Antimicrobial class: Macrolide

Average serum half life: pediatrics: 54.5 hours

Route of Elimination: 50% excreted unchanged in bile.

6-14% excreted unchanged in urine.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.